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Objectives: Gastrointestinal symptoms, particularly
pyrosis, complicate nonsteroidal anti-inflammatory
drug (NSAID) use. NSAIDs cause esophageal injury, and
H, blockers are often prescribed for, and successfully
control, NSAID-related .symptoms. To determine
whether NSAIDs can induce gastroesophageal reflux, we
studied the effect of a commonly used NSAID. naproxen,
on relltix parameters and esophageal function. Methods:
Nine healthy volunteers (five males, four females, age
2.V-34 yr) were studied. After basal measurements were
taken, (he subjects randomly received naproxen 500 mg
p.o. b.Ld. or placebo for 1 wk. On day 6, the subjects
underwent esophageal manometry with a water-per-
fu.sed system and Dent sleeve. Body pressures, contrac-
tion velocity, and duration of contraction were recorded
in the distal 7 cm of the esophagus. The lower esophageal
sphincter pressure (I.KSP) and nuniher of transient re-
laxations (TLESRs) were monitored. This was followed
by 24-h pH monitoring. The subjects then crossed over
to the other drug after a minimum 14-day wash-out
period. Results: No subject experienced any GI symp-
toms during the study. One subject developed reflux-
induced symptoms a few months after completing the
study and was excluded from the analysis. The total
fraction of time (pH < 4) was 4.9 ± 1.0% in the basal
state, 5.5 ± 1.4% on placebo, and 5.4 ± 1.5% on
naproxen. These differences were not significant. The
number of reflux episodes and the e.sophageal clearance
time were not aflected by naproxen. The LESP in the
basal state was 32.1 ± 5.6 mm Hg, 32.3 ± 4.2 mm Hg on
placebo, and 29.9 ± 3.3 mm Hg on naproxen {p = NS).
Tbe number of TLESRs per 30 minutes in tbe basal state
was 3.5 ± 0.9, 4.6 ± 1.2 on placebo, and 5.8 ± 1.0 on
naproxen {p = NS). Tbe speed and duration of contrac-
tions were not alTected by naproxen. The excluded sub-
ject had marked basal retlux (total fraction of time pH <
4 = 10.7%), low LESP {8 mm Hg), and a marked in-
crease in reflux on naproxen (total fraction of time pH <
4 = 53%). Conclusions: Naproxen did not induce reflux
in normal subjects, althougb reflux did increase in some
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subjects. Naproxen had no significant effect on motility
parameters. Our data suggest that NSAIDs do not im-
pair the anti-reflux barrier or induce reflux. Pyrosis
experienced during NSAID use may not arise from the
esophagus or may reflect altered e.sophageal sensitivity.
A single suhject with decreased LESP and asympUmiatic
increased acid exposure in the basal state had a marked
increase in reflux on naproxen. This person subse-
quently developed symptomatic gastroesophageal retlux.
The effect of NSAIDs on individuals with a propensity to
reflux deserves further study.
INTRODUCTION
Gastrointestinal side effects frequently complicate the use
of nonsterojdal anti-inflammatory drugs (NSAID) in clinical
practice. NSAID-induced gastric and duodenal ulcers have
received the greatest attention, but esophageal complica-
tions of NSAID are also recognized. NSAIDs have been
linked to the development of benign esophageal strictures
and esophageal ulceration (I, 2). Endoscopic investigation
of chronic NSAID users has observed the presence of esoph-
agitis in 20% of the users (3). In addition to the life-
threatening complications, such as bleeding or perforated
ulcers, NSAIDs commonly induce dyspepsia, heartburn.
nausea, and vomiting. Up to 50% of subjects report these
symptoms in short term clinical trials, and chronic users may
experience such symptoms less frequently (4). Mucosal injury
correlates po(.)rly with dyspeptic symptoms, and many symp-
tomatic patienis have a normal upper GI endoscopy (5).
Symptomatic NSAID users are frequently prescribed H^
receptor antagonists to control symptoms, despite evidence that
standard doses of these drugs cannot prevent NSAID-induced
gastric ulcers (6). Recent clinical trials have confirmed the
efficacy of cimetidine 4(K) mg h.i.d. in patients with endosco-
py-negative NSAID-induced symptoms (7, 8), suggesting a
relationship between acid secretion and dyspeptic symptoms.
Prostaglandins are known to affect both the lower esophageal
sphincter and body smooth muscle (9, 10), so we hypothesized
that NSAIDs may induce symptoms by increasing esophageal
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FIG. I. Bsophageat acid exposure time for each volunteer during placebo
iind naproxen ndministration. Each data point reflects the percentage of
time esophageal pH was les.*; than 4 during each monitored period.
acid exposure, thus explaining the efficacy of acid suppression
in ameliorating symptoms.
Delailed studies of the effect of NSAIDs on the esopha-
geal function and gastroesophageal reflux have not been
performed. A prior study in humans has demonstrated that
a single rectal dose of indomethacin actually increased
lower esophageal sphincter pressure (LESP), consistent with
animal data that certain prostaglandins, especially PGEj,
decrease LESP (11). Histological studies have suggested
that NSAID ingestion tnay actually reduce the severity of
esophageal inflammation in both experimental esophagitis
(12) and in rheumatic patients versus control subjects (13).
Endoscopic studies confirtn that NSAID users have far
less esophagitis than gastric or duodenal injury and that
local irritative toxicity, not esophageal reflux, is the pre-
sumed predominant mechanism of esophageal injtiry. Cy-
clooxygenase inhibition could potentially effect the antire-
flux barrier via effects on either the LES or esophageal
clearance mechanisms, so we studied normal volunteers to
determine whether a commonly prescribed NSAID,
naproxen, taken for 1 wk. could induce reflux or signifi-
cantly affect esophageal motility parameters.
METHODS
Nine healthy, nonsmoking volunteers (five males, four
females), mean age 25 yr (range 23-34). without a past
history of heartburn or intolerance to NSAIDs, were studied.
None of the subjects was taking any medication, Subjects
who were pregnant, tobacco- or heavy alcohol-users and
individuals with recent use of, or allergy to, nonsteroidal
anti-inflammatory drugs were excluded.
This study used a randomized, double-blind, placebo-
controlled, crossover design. After a basal esophageal ma-
nometry study and 24-h pH monitoring, each subject re-
ceived, on separate occasions 2 wk apart, cither placebo or
naproxen 500 mg h.i.d. for 1 wk.
A symptom diary was completed by all subjects. On day
6 of study medication, the subjects underwent esophageal
manometry and placement of a 24-h pH probe. The pH
probe was removed within 12 h of last dose of naproxen.
After a minimum 2-wk wash-out period, the volunteers
crossed over to the other study medication. They returned on
day six for repeat evaluation with esophageal manometry
and placement of a 24-h pH probe.
Esophageal manometric studies and ambulatory 24-h pH
monitoring were performed using standard techniques (14.
15). Contractions were recorded from an 8-!umen polyvinyl
catheter with attached Dent sleeve (Arndorfer Medical Spe-
cialties. Greendale. WI). The distal four openings were I cm
apart at 90° angles, and the four proximal openings were at
5-cm intervals. Each lumen was continuously perfused with
distilled water at a rate of 0.5 ml/minute from a low com-
pliance, pneumohydraulic capillary-infusion system. The
catheter was connected to external transducers with output
to a physiograph (Beckman 611, Sensormcdics. Anaheim
CA). LESP was recorded using the Dent sleeve. Esophageal
peristalsis was assessed after 10 wet swallows (5 ml of water
given at 30-s intervals). After each swallow, the amplitude,
velocity, and duration of esophageal body contractions were
measured al 2 and 7 cm above the lower esophageal sphinc-
ter. The frequency of transient lower esophageal sphincter
relaxations were also recorded over a 30-minute basal pe-
riod.
The 24-h pH monitor probe (Synectics Medical Inc..
Irving TX) was placed 5 cm above the manometrically
defined lower esophageal sphincter and was connected to a
belt-held computer. The frequency and duration of reflux
events were measured. The results were analyzed for per-
cent time pH <4 (total, supine, upright), number of reflux
events (total, supine, upright), esophageal clearance time per
reflux event (total, supine, upright), and number of reflux
events greater than 5 minutes.
Statistical analysis
The effect of naproxen on the 24-h pH monitor and
esophageal manometry study data were compared to the
placebo data using the Student's / test for paired data. A p
value of <0.05 was considered significant. This research
study was approved by the Institutional Review Board at
University of Michigan Medical Center,
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TABLE 1
Results of 24'h pH Monitoring
Eaaal Placebo Naproxen Value
Total % p H < 4 4.9 2:t.ll 5.5 ± 1.4 5.4 ± 1.5 NS
Reflux evenis (total) 57.8 ± 2t.3 45.4 ± 11.2 36.1 ± 7.1 NS
Esophageal clearance t.4 i 0.4 1.3 ± 0.2 1.5 ± 0.4 NS
(tolal) min/reflux
event




Re.<iults of Esopkageal Manometric Studies
Basal Placebo Naproxen p Value
LESP (mm Hg) 32.1 ± 5.6 32.3 ± 4.2 29.9 ± 3.3 NS
Amplitude (mm Hg) 77.9 ± 16.6 83.4 ± 12.6 91.1 ± 15.0 NS
Duration (s) 2.82 ± 0.2 2.8 ± 0.14 2.9 ± O.I NS
Speed (cnVs) 9.32 ± 1.0 7.7 ± 1.3 8.5 ± 1.4 NS




No subject developed pyrosis or any other GI symptom
on naproxen. A number of months after completion of the
study, one of the subjects developed hoarseness and sore
throat requiring evaluation. Reflux was felt to be the etiol-
ogy, and the patient was successfully treated with an H2
receptor antagonist. This subject was excluded from the
analysis, and her studies are described in detail separately.
The eight remaining subjects had mild, asymptomatic reflux
in the basal state with the total percent of time pH <4 = 4.9
± 1.0% (upper limit of normal for our laboratory 4%). The
total percent of time (pH <4) was 5.5 ± 1.4% on placebo
and 5.4 ± 1.5% on naproxen treatment {p not significant).
As seen in Figure 1. the total percent time pH < 4 on
naproxen for each subject was variable. The number of
reflux events, percent of time (pH <4) in the supine or
upright positions, and esophageal clearance time were not
significantly affected by naproxen use (Table 1). The ex-
cluded subject had a markedly decreased LESP (8 mm Hg)
and reflux (total fraction of time pH <4 = 10.7%) in the
basal state, On naproxen, this subject developed marked
asymptomatic reflux (total time pH <4 = 53%).
Esophageal motility studies
Esophageal manometry studies determined the LESP,
amplitude, duration, and speed of peristaltic contractions, in
addition to the number of transient lower esophageal sphinc-
ter relaxations (TLESR) over a 3n-minute monitoring pe-
riod. LESP was 32.1 ± 5.6 mm Hg in the basal state, 32.3
± 4.2 mm Hg on placebo, and 29.9 ± 3.3 tnm Hg {p = NS)
on naproxen. The number of TLESRs in the basal state was
3.5 ± 0.9, 4.6 ± 1.2 on placebo, and 5.7 ± 1.0 on naproxen
{p = NS). The speed, duration, and amplitude of contrac-
tions were not significantly affected by naproxen (Table 2).
There was no relationship between the LESP or number of
TLESRs and the results of 24-h pH monitoring.
DISCUSSION
Our data have demonstrated that in healthy normal indi-
viduals, 1 wk of naproxen does not induce gastroesophageal
reflux or significantly affect parameters of esophageal func-
tion. Although prostaglandins clearly are implicated in con-
trol of esophageal smooth muscle contraction, different
prostaglandin subtypes have been reported to either increase
or decrease LESP (9. 11). Animal models of reflux esoph-
agitis have demonstrated that esophageal inflammation is
associated with increases in local prostaglandin production,
which may contribute to further LES incompetence, an
effect blocked by indomethacin (12, 16). Our results in
humans suggest that when cyclooxygenase is inhibited, ex-
isting overlapping control mechanisms (neural, hormonal)
maintain esophageal function. This process may represent
the esophageal equivalent to gastric adaptation to NSAID
injury in the stomach (17).
If NSAIDs do not appear to effect esophageal motility or
induce reflux, is the reflux-like dyspepsia and pyrosis ex-
perienced during NSAID therapy, which seems to respond
to acid inhibition, due to increased gastroesophageal reflux?
Although our acute study in healthy subjects who experi-
enced no symptoms cannot directly address this question,
two possibilities are suggested by our results. One subject in
our study did experience a large increase in reflux on
naproxen, so there may be interindividual susceptibility to
the effects of NSAIDs. similar to the case for upper GI
mucosal injury. Although there was no relationship between
LESP and esophageal acid exposure overall, the subject
with marked increased reflux on naproxen had the lowest
basal LESP of the study group. Further study of patients
who experience pyrosis on NSAIDs and the effect of
NSAIDs on individuals with a reflux propensity are war-
ranted.
Another possibility is that NSAIDs may affect esophageal
sensitivity to physiological levels of retlux. because acid
perfusion or balloon distention of the esophagus can identify
individuals with normal pH monitoring who have esopha-
geal symptoms (18, 19). Prospective studies using 24-h pH
monitoring and studies of esophageal sensitivity in symp-
tomatic NSAID users and reflux patients are required to
answer these questions.
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